Tender Details

Country: USA
Summary: 2026 NIAID DMID Omnibus Broad Agency Announcement
UST Ref No: 109643478
Deadline: 21 Feb 2025
Financier: Self Financed
Purchaser Ownership: Government
Tender Value: Refer Document
Notice Type: Tender
Document Ref. No.: HHS-NIH-NIAID-BAA2025-1
Purchaser's Detail:
Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details.
Login to see details
Description:
Description
Introduction:
The National Institute of Allergy and Infectious Diseases (NIAID), one of 27 institutes of the National Institutes of Health, an agency within the Department of Health and Human Services (DHHS), conducts and supports research to understand, treat, and ultimately prevent the myriad infectious, immunologic, and allergic diseases that threaten millions of human lives. Through a variety of research grants and contracts, NIAID-s Division of Microbiology and Infectious Diseases (DMID) specifically supports extramural research to develop new medical countermeasures (MCMs) against potential agents of bioterrorism, drug-resistant pathogens, and emerging and re-emerging infectious diseases. This Broad Agency Announcement (BAA) is soliciting proposals to advance the research and development of promising candidate therapeutics, vaccines, and diagnostics for biodefense and emerging infectious diseases.
The Research Areas included in this NIAID OMNIBUS BROAD AGENCY ANNOUNCEMENT No. HHS-NIH-NIAID-BAA2025-1, as well as the projected amounts of available funding, are discussed below. Dates for receipt of proposals will be identified separately for EACH Research Area within the solicitation.
Description:
Research Area 001 - Development of Candidate Therapeutics, Vaccines, and In Vitro Diagnostics for Antimicrobial-Resistant (AMR) Bacterial or Fungal Pathogens
For Research Area 001, there are three (3) separate Topics - A, B, and C. Offerors may submit a proposal in response to Topics A, B, and/or C. If proposing to multiple Topics, Offerors must submit separate technical and business proposals for each Topic.
Topic A: Therapeutics for AMR Bacterial or Fungal Pathogens
The objective of Topic A is to develop new therapeutic products against severe infections and/or drug-resistant strains of the following bacterial and fungal pathogens:
a. Pseudomonas aeruginosa, and/or Acinetobacter baumannii; OR
b. Candida auris, Crypt...
Documents:

Pre-solicitation-Notice-BAA2025-1-Final.pdf

If you are registered member, kindly login to view full details of this tender notice:

2026 NIAID DMID Omnibus Broad Agency Announcement - USA Tender

The HEALTH AND HUMAN SERVICES, DEPARTMENT OF | NATIONAL INSTITUTES OF HEALTH, a Government sector organization in USA, has announced a new tender for 2026 NIAID DMID Omnibus Broad Agency Announcement. This tender is published on USARFP under UST Ref No: 109643478 and is categorized as a Tender. Interested and eligible suppliers are invited to participate by reviewing the tender documents and submitting their bids before the deadline on 2025-02-21.

The estimated tender value is Refer Document, and full details, including technical specifications and submission requirements, are provided in the official tender documents. Ensure all submissions meet the criteria outlined to be considered for evaluation.